Pharmaceutical composition for treating premature ovarian failure as well as application and preparation method thereof

A premature ovarian failure and composition technology, which is applied in the field of pharmaceutical compositions for the treatment of premature ovarian failure, can solve the problems of not being able to meet the reproductive needs of patients, delaying treatment time, and high costs

Pending Publication Date: 2022-07-15
SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of such drugs cannot solve fertility problems, and may also increase the risk of recurrence of hormone-sensitive tumors such as ovarian cancer and breast cancer; 2. Use of gonadotropin-releasing hormone analogs: including GnRH agonists or GnRH antagonists, which are similar drugs Still can not meet the reproductive needs of patients; 3. Fertilized egg and embryo cryopreservation technology: Although the pregnancy rate is 18%, it is not suitable for unmarried women, and it is very likely to delay the treatment time; 4. Oocyte cryopreservation technology and ovarian Cortex cryopreservation and transplantation technology: the pregnancy rate of this operation is less than 3%, the technology is not yet mature, and the cost is high
[0005] In short, the existing treatment methods cannot fundamentally treat premature ovarian failure, and it is urgent to open up a new way and solve the fertility problem of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating premature ovarian failure as well as application and preparation method thereof
  • Pharmaceutical composition for treating premature ovarian failure as well as application and preparation method thereof
  • Pharmaceutical composition for treating premature ovarian failure as well as application and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0080] In addition, the application also provides a preparation method of a pharmaceutical composition for treating premature ovarian failure, comprising:

[0081] Get the traditional Chinese medicine Astragalus, and extract the total astragalus saponins, astragaloside I, astragaloside II, astragaloside III and astragaloside IV in the pharmaceutical composition for treating premature ovarian failure as described in any one of the foregoing according to the natural product extraction method; Get one or more of the combinations to obtain the pharmaceutical composition for treating premature ovarian failure;

[0082] Among them, the natural product extraction method can be decoction, reflux extraction, ultrasonic extraction, microwave extraction, enzyme extraction, supercritical extraction, flash extraction, high-speed countercurrent chromatography and high performance liquid chromatography. one or more combinations.

[0083] As mentioned above, the traditional Chinese medicine ...

Embodiment 1

[0101] Example 1: Confirmation of components of monomers and extracts

[0102] Astragaloside total saponins, astragaloside I, astragaloside II, astragaloside III and astragaloside IV were separated and purified, and the above components were confirmed.

[0103] Specific methods and results:

[0104] In this example, the total saponin extract of Astragalus, as well as Astragaloside I, Astragaloside II, Astragaloside III and Astragaloside IV were tested separately by high-resolution LC / MS to confirm their components.

[0105] Test Conditions:

[0106] Astragalus saponins I, II, III, IV and total astragalus saponins were respectively dissolved in 50% acetonitrile with a final concentration of 5 ppm. Using UPLCBEH C18 column (100mm×2.1mm, 1.7μm), 0.1% aqueous formic acid and acetonitrile were used as mobile phase A and mobile phase B, respectively, gradient elution (0-2.5min, 95%A→70%A; 2.5 -4.5min, 70%A→65%A; 4.5-6min, 65%A; 6-7min, 65%A→60%A; 7-9min, 60%A→40%A; 9-14min, 40% ...

Embodiment 2-4

[0118] Experimental Materials:

[0119] 1. Sample to be tested: total Astragalus saponins, Astragalus saponins I, Astragalus saponins II, Astragalus saponins III and Astragalus saponins IV.

[0120]2. Reagents and samples: pregnant horse serum gonadotropin PMSG, prospec hot-272; DMEM-F12 phenol red-free medium, Thermo; fetal bovine serum, Gibco; Accumax TM solution, Sigma; Hanks buffer, Thermo; CellTiter-Glo Luminescent Cell Viability Assay, Promega; Doxorubicin, Sigma; Mouse Follicle Stimulating Hormone (FSH) ELISA Kit, bio-swamp; Mouse Estradiol (E2) ELISA kit, bio-swamp; 4% paraformaldehyde tissue fixative, bio-swamp; hematoxylin-eosin staining solution, Baso; 1% hydrochloric acid alcohol, Baso.

[0121] 3. Instruments and equipment: cell incubator, Thermo; inverted microscope, ZEISS; inverted dissecting microscope, ZEISS; small cryogenic centrifuge, Eppendorf; cell counter, Countess II; multi-function microplate detector, BioTek.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for treating premature ovarian failure as well as application and a preparation method of the pharmaceutical composition. According to the pharmaceutical composition for treating premature ovarian failure, the effects of tonifying qi and strengthening superficies, draining toxin and pus, healing sore and promoting tissue regeneration, engendering liquid and nourishing blood, inducing diuresis to alleviate edema and the like of astragalus membranaceus serving as a Chinese herbal medicine are fully utilized; one or a combination of more of the astragaloside extract, the astragaloside I, the astragaloside II, the astragaloside III and the astragaloside IV is used as a component of the pharmaceutical composition, so that the premature ovarian failure symptom caused by ovarian injury can be effectively relieved and treated; toxic and side effects and carcinogenic risks existing in an existing treatment method are avoided, and the treatment cost is greatly reduced.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating premature ovarian failure, an application and a preparation method thereof. Background technique [0002] Premature ovarian failure (POF) refers to the phenomenon of amenorrhea before the age of 40 in women caused by ovarian failure. It is characterized by primary or secondary amenorrhea accompanied by increased blood gonadotropin levels and decreased estrogen levels, accompanied by a series of hypoestrogenic symptoms of varying degrees, such as hot flashes and sweating, facial flushing, and low libido. [0003] Premature ovarian failure is a syndrome with multiple etiologies, the etiology of which is unknown in most cases. Mainly divided into the following aspects, including: genetic factors, immune factors, surgery, chemotherapy, radiotherapy and environmental toxins, enzyme deficiencies, psychological factors, idiopathic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K36/481A61P15/00A61K125/00
CPCA61K31/7048A61K36/481A61P15/00A61K2300/00
Inventor 张文勇肖燕琳李绚栾合密张静张懿徐锦岳蓝章彰
Owner SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap